KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Long-Term Investments (2019 - 2025)

Historic Long-Term Investments for Adaptive Biotechnologies (ADPT) over the last 6 years, with Q3 2025 value amounting to $4.0 million.

  • Adaptive Biotechnologies' Long-Term Investments fell 8308.47% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 8308.47%. This contributed to the annual value of $33.7 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Long-Term Investments stood at $4.0 million, which was down 8308.47% from $24.1 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Long-Term Investments high stood at $217.4 million for Q3 2021, and its period low was $4.0 million during Q3 2025.
  • Over the past 4 years, Adaptive Biotechnologies' median Long-Term Investments value was $36.5 million (recorded in 2024), while the average stood at $75.4 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first soared by 122016.88% in 2021, then tumbled by 9093.84% in 2022.
  • Adaptive Biotechnologies' Long-Term Investments (Quarter) stood at $217.1 million in 2021, then crashed by 90.93% to $19.7 million in 2022, then soared by 70.88% to $33.7 million in 2024, then crashed by 88.01% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $24.1 million for Q2 2025, and $39.4 million during Q1 2025.